# Trade Mark Journal No.2026/027 3 July 2026

## WO0000001922071 (5,42)

Office of origin: United States of America

Date of International Registration:17 April 2026
Date of designation in the UK: 17 April 2026

International priority date claimed: 28 October 2025 (Tonga)

Class 5
  Pharmaceuticals; pharmaceutical preparations; pharmaceuticals for the treatment of mental health conditions; pharmaceutical preparations for the treatment of mental health conditions; pharmaceutical preparations, namely, psychotropic, psychoactive, and psychedelic medicinal preparations for the treatment of mental health conditions; pharmaceutical preparations for the treatment of psychiatric diseases and disorders, namely, anxiety, depression, post-traumatic stress disorder, and mood disorders; pharmaceutical preparations for the treatment of substance-use and addictive disorders.
Class 42
  Drug discovery services; pharmaceutical drug development services; pharmaceutical research and development; pharmaceutical research services; providing medical and scientific research information in the fields of pharmaceuticals; research and development in the pharmaceutical and biotechnology fields; pharmaceutical research and development in the fields of psychiatry, neurology, and addiction medicine; medical and scientific research, namely, conducting clinical trials for others in the field of psychedelic-based therapeutics.

Definium Therapeutics US, Inc.

Representative: John Paul Oleksiuk Cooley LLP, 1299 Pennsylvania Ave. NW STE 700, Washington DC 20004, UNITED STATES OF AMERICA